A novel immunotherapy prognostic score for patients with pretreated advanced urInary TrAct CArcinoma from the subgroup analysis of the SAUL study: the ITACA Score

FORNARINI, Giuseppe; REBUZZI, Sara E.; BUTI, Sebastiano; RESCIGNO, Pasquale; MERSEBURGER, Axel; STERNBERG, Cora N.; GIORGI, Ugo de; BASSO, Umberto; MARUZZO, Marco; GIANNATEMPO, Patrizia; Ponzano, Marta; GIUNTA, Emilio F.; CATALANO, Fabio; MURIANNI, Veronica; DAMASSI, Alessandra; CREMANTE, Malvina; GANDINI, Annalice; PUGLISI, Silvia; OBISPO, Miguel A. LLAJA; Signori, Alessio; BANNA, Giuseppe L.

doi:10.23736/s2724-6051.22.05135-7

Cited by 4 publications

(1 citation statement)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Regarding the treatment of mUC, Fornarini et al analyzed a real-world cohort of more than 250 patients treated in Italy with atezolizumab in the phase IIIb SAUL trial and found a significant association between survival outcomes (PFS and OS), NLR (cut-off: 3, 3.65, and 5), and SII (cut-off: 884 and 1375) [ 12 ]. On analyzing all patients enrolled in the trial, they confirmed a prognostic role for NLR (HR for OS: 1.66 and 2.17 for NLR cut-off 3 and 5, respectively) and SII (HR for OS: 2.16 and 2.19 for SII cut-off 884 and 1375, respectively); consequently, they were able to create a novel prognostic score for OS [ 25 ].…”

Section: Discussionmentioning

confidence: 92%

Prognostic Role of Systemic Inflammation Indexes in Metastatic Urothelial Carcinoma Treated With Immunotherapy

Dionese,

Basso,

Pierantoni

et al. 2023

Future Sci. OA

View full text Add to dashboard Cite

Aim: Inflammation indexes had been associated with overall survival (OS) and immune-related adverse events (irAEs) in patients treated with immune checkpoint inhibitors (ICIs). Materials & methods: in 72 patients treated with ICIs for metastatic urothelial carcinoma (mUC) we evaluate differences in OS, response rate and toxicities, according to baseline inflammation indexes values. Results: neutrophil-to-lymphocite ratio (NLR) <3 was associated to longer progression-free survival (PFS; 4.9 vs 3.1 months) and OS (15.7 vs 7.6 months); monocyte-to-lymphocite ratio (MLR) <0.4 was associated to longer PFS (4.6 vs 2.8 months). Overall response rate (ORR), disease control rate (DCR) were higher in these patients. Patients with an irAE had longer PFS and OS. Conclusion: baseline inflammatory indexes are prognostic for mUC patients treated with ICIs.

show abstract

Section: Discussionmentioning

confidence: 92%

Prognostic Role of Systemic Inflammation Indexes in Metastatic Urothelial Carcinoma Treated With Immunotherapy

Dionese,

Basso,

Pierantoni

et al. 2023

Future Sci. OA

View full text Add to dashboard Cite

show abstract

Predictive Value of Pretreatment Neutrophil to Albumin Ratio in Response to Neoadjuvant Chemotherapy of Breast Cancer

Deng,

Zhao,

Nong

et al. 2024

BCTT

View full text Add to dashboard Cite

Background:The immune system appears to play a crucial role in how breast cancer responds to chemotherapy. In this study, we investigated a peripheral marker of immune and inflammation named the neutrophil to albumin ratio (NAR) to explore its potential relationship with pathological complete response (pCR) in locally advanced breast cancer patients who underwent neoadjuvant chemotherapy (NAC). Methods: We conducted a retrospective analysis of 212 consecutive breast cancer patients who received NAC. The NAR was calculated by examining the complete blood cell count and albumin level in peripheral blood before starting NAC. Through ROC curve analysis, we determined the optimal cutoff value for NAR as 0.0877. We used Pearson's chi-square test or Fisher's exact test to evaluate the relationship between NAR and pCR, as well as other clinical and pathological characteristics. Logistic regression models were employed for univariate and multivariate analyses. Results: The results of both univariate and multivariate logistic regression analyses showed that NAR was associated with tumor pathological regression. The NAR high group had a higher pCR rate compared to the NAR low group ]; p = 0.002). Conclusion:According to this study, it was observed that patients with breast cancer who had high levels of NAR were more likely to achieve pCR when undergoing NAC.

show abstract

Prognostic models for patients with metastatic urothelial carcinoma: why use them?

Maffezzoli

Campobasso

REBUZZI

et al. 2023

Minerva Urol Nephrol

View full text Add to dashboard Cite

A novel immunotherapy prognostic score for patients with pretreated advanced urInary TrAct CArcinoma from the subgroup analysis of the SAUL study: the ITACA Score

Cited by 4 publications

References 30 publications

Prognostic Role of Systemic Inflammation Indexes in Metastatic Urothelial Carcinoma Treated With Immunotherapy

Prognostic Role of Systemic Inflammation Indexes in Metastatic Urothelial Carcinoma Treated With Immunotherapy

Predictive Value of Pretreatment Neutrophil to Albumin Ratio in Response to Neoadjuvant Chemotherapy of Breast Cancer

Prognostic models for patients with metastatic urothelial carcinoma: why use them?

Contact Info

Product

Resources

About